{{Rsnum
|rsid=2236930
|Gene=IL1R2
|Chromosome=2
|position=102009418
|Orientation=minus
|GMAF=0.2259
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=IL1R2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 80.0 | 20.0 | 0.0
| HCB | 64.4 | 31.1 | 4.4
| JPT | 48.9 | 40.0 | 11.1
| YRI | 49.2 | 38.1 | 12.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 64.4 | 31.1 | 4.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2236930
|Name_s=rs2236930 A/T IL1R2
|Gene_s=IL1R2
|Feature=
|Evidence=PubMed ID:20157331
|Annotation=Risk or phenotype-associated allele: Not specified. Phenotype: This SNP was associated with clearance of docetaxel. Study size: 31. Study population/ethnicity: Patients with Non-Small-Cell Lung Carcinoma. Significance metric(s): p = 0.0045 (ANOVA); p = 0.052 (QMIS); p = 0.0004 (KW) Type of association: PK.
|Drugs=docetaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291796
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2236930
|overall_frequency_n=24
|overall_frequency_d=128
|overall_frequency=0.1875
|n_genomes=19
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}